Stock Track | Y-mAbs Stock Plunges Over 11% as Q3 Earnings Miss Estimates on Higher Costs

Stock Track11-08

Shares of Y-mAbs Therapeutics, Inc. (YMAB) plummeted over 11% in pre-market trading on Wednesday, November 8, 2024, after the biopharmaceutical company reported disappointing third-quarter financial results, weighed down by higher-than-expected operating expenses.

For the quarter ended September 30, 2024, Y-mAbs reported total net revenues of $18.5 million, a 10% decline from $20.5 million in the same period last year. The company's lead product, DANYELZA, generated net product revenues of $18.5 million, with $15.3 million coming from the U.S. market and $3.1 million from ex-U.S. markets. The decline in total net revenues was primarily driven by lower international sales.

However, the company's operating costs and expenses for the quarter rose to $27 million, compared to $28.2 million a year ago. The increase was primarily driven by higher selling, general, and administrative expenses, which jumped to $13.6 million from $10.2 million in the third quarter of 2023. The higher SG&A expenses were attributable to factors such as increased personnel costs, professional and consulting fees, and severance charges related to the former Chief Financial Officer's separation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment